---
document_datetime: 2025-12-02 05:47:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fareston.html
document_name: fareston.html
version: success
processing_time: 0.1082365
conversion_datetime: 2025-12-26 21:14:33.765807
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fareston

[RSS](/en/individual-human-medicine.xml/66114)

##### Authorised

This medicine is authorised for use in the European Union

toremifene Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).

Expand section

Collapse section

## What is Fareston?

Fareston is a medicine that contains the active substance toremifene. It is available as white, round tablets (60 mg).

## What is Fareston used for?

Fareston is used to treat hormone-dependent metastatic breast cancer in women who have been through the menopause. 'Metastatic' means that the cancer has spread to other parts of the body. Fareston is not recommended for patients with oestrogen-receptor-negative tumours (where the cancer cells do not have receptors for the hormone oestrogen on their surface).

The medicine can only be obtained with a prescription.

## How is Fareston used?

The recommended dose of Fareston is one tablet once a day. It should be used with caution in patients who have problems with their liver.

## How does Fareston work?

Most types of breast cancer grow in response to the hormone oestrogen. The active substance in Fareston, toremifene, is an anti-oestrogen. It attaches to the receptors for oestrogen on the surface of cells, where its main effect is to block the effects of the hormone. As a result, the tumour cells are not stimulated to grow by oestrogen and the growth of the tumour is reduced.

## How has Fareston been studied?

The effects of Fareston were first tested in experimental models before being studied in humans.

Fareston has been studied in 1,869 postmenopausal women with metastatic breast cancer in four main studies. The effects of Fareston were compared with those of tamoxifen (another anti-oestrogen used to treat breast cancer). The main measures of effectiveness were response rate (the number of patients whose tumours responded to treatment), time to progression (the length of time until the disease got worse) and survival.

## What benefit has Fareston shown during the studies?

The effectiveness of Fareston and tamoxifen were equivalent. Looking at the results of the three largest main studies taken together, patients taking Fareston had similar response rates, times to progression and survival rates as the patients taking tamoxifen. This was confirmed in the fourth study.

## What is the risk associated with Fareston?

The most common side effects with Fareston (seen in more than 1 patient in 10) are hot flushes and sweating. For the full list of all side effects reported with Fareston, see the Package Leaflet.

Fareston should not be used in people who may be hypersensitive (allergic) to toremifene or any of the other ingredients. It must not be used on a long-term basis in patients who have endometrial hyperplasia (thickening of the lining of the womb) or severe liver problems. Fareston must not be used in patients with 'QT prolongation' (a disruption of the electrical activity of the heart), electrolyte disturbances (altered levels of salts in the blood) especially hypokalaemia (low potassium levels), bradycardia (a very slow heart rate), heart failure (an inability of the heart to pump enough blood to the rest of the body) or a history of symptomatic arrhythmias (abnormal heart rhythms), or in patients also taking other medicines that can cause QT prolongation. A list of these medicines is given in the Package Leaflet.

## Why has Fareston been approved?

The Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits and risks of Fareston were comparable to those of tamoxifen in women with oestrogen-receptor-positive tumours. Therefore, the Committee decided that Fareston's benefits are greater than its risks for the first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. The Committee recommended that Fareston be given marketing authorisation.

## Other information about Fareston

The European Commission granted a marketing authorisation valid throughout the European Union for Fareston on 14 February 1996. The marketing authorisation was renewed on 14 February 2001 and on 14 February 2006. The marketing authorisation holder is Orion Corporation.

Fareston : EPAR - Summary for the public

English (EN) (40.17 KB - PDF)

**First published:** 02/04/2009

**Last updated:** 02/04/2009

[View](/en/documents/overview/fareston-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-473)

български (BG) (165.8 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/bg/documents/overview/fareston-epar-summary-public_bg.pdf)

español (ES) (42.15 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/es/documents/overview/fareston-epar-summary-public_es.pdf)

čeština (CS) (155.95 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/cs/documents/overview/fareston-epar-summary-public_cs.pdf)

dansk (DA) (41.12 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/da/documents/overview/fareston-epar-summary-public_da.pdf)

Deutsch (DE) (41.97 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/de/documents/overview/fareston-epar-summary-public_de.pdf)

eesti keel (ET) (40.75 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/et/documents/overview/fareston-epar-summary-public_et.pdf)

ελληνικά (EL) (160.86 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/el/documents/overview/fareston-epar-summary-public_el.pdf)

français (FR) (42.23 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/fr/documents/overview/fareston-epar-summary-public_fr.pdf)

italiano (IT) (41.43 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/it/documents/overview/fareston-epar-summary-public_it.pdf)

latviešu valoda (LV) (158.42 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/lv/documents/overview/fareston-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (153 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/lt/documents/overview/fareston-epar-summary-public_lt.pdf)

magyar (HU) (147.81 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/hu/documents/overview/fareston-epar-summary-public_hu.pdf)

Malti (MT) (157.91 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/mt/documents/overview/fareston-epar-summary-public_mt.pdf)

Nederlands (NL) (41.37 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/nl/documents/overview/fareston-epar-summary-public_nl.pdf)

polski (PL) (162.92 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/pl/documents/overview/fareston-epar-summary-public_pl.pdf)

português (PT) (41.83 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/pt/documents/overview/fareston-epar-summary-public_pt.pdf)

română (RO) (146.11 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/ro/documents/overview/fareston-epar-summary-public_ro.pdf)

slovenčina (SK) (151.65 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/sk/documents/overview/fareston-epar-summary-public_sk.pdf)

slovenščina (SL) (144.18 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/sl/documents/overview/fareston-epar-summary-public_sl.pdf)

Suomi (FI) (41.04 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/fi/documents/overview/fareston-epar-summary-public_fi.pdf)

svenska (SV) (41.17 KB - PDF)

**First published:**

02/04/2009

**Last updated:**

02/04/2009

[View](/sv/documents/overview/fareston-epar-summary-public_sv.pdf)

## Product information

Fareston : EPAR - Product Information

English (EN) (166.06 KB - PDF)

**First published:** 03/04/2009

**Last updated:** 30/07/2024

[View](/en/documents/product-information/fareston-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-350)

български (BG) (200.94 KB - PDF)

**First published:**

30/07/2024

[View](/bg/documents/product-information/fareston-epar-product-information_bg.pdf)

español (ES) (167.61 KB - PDF)

**First published:**

30/07/2024

[View](/es/documents/product-information/fareston-epar-product-information_es.pdf)

čeština (CS) (177.32 KB - PDF)

**First published:**

30/07/2024

[View](/cs/documents/product-information/fareston-epar-product-information_cs.pdf)

dansk (DA) (174.99 KB - PDF)

**First published:**

30/07/2024

[View](/da/documents/product-information/fareston-epar-product-information_da.pdf)

Deutsch (DE) (182 KB - PDF)

**First published:**

30/07/2024

[View](/de/documents/product-information/fareston-epar-product-information_de.pdf)

eesti keel (ET) (171.03 KB - PDF)

**First published:**

30/07/2024

[View](/et/documents/product-information/fareston-epar-product-information_et.pdf)

ελληνικά (EL) (191.09 KB - PDF)

**First published:**

30/07/2024

[View](/el/documents/product-information/fareston-epar-product-information_el.pdf)

français (FR) (189.3 KB - PDF)

**First published:**

30/07/2024

[View](/fr/documents/product-information/fareston-epar-product-information_fr.pdf)

hrvatski (HR) (164.46 KB - PDF)

**First published:**

30/07/2024

[View](/hr/documents/product-information/fareston-epar-product-information_hr.pdf)

íslenska (IS) (186.91 KB - PDF)

**First published:**

30/07/2024

[View](/is/documents/product-information/fareston-epar-product-information_is.pdf)

italiano (IT) (173.92 KB - PDF)

**First published:**

30/07/2024

[View](/it/documents/product-information/fareston-epar-product-information_it.pdf)

latviešu valoda (LV) (177.39 KB - PDF)

**First published:**

30/07/2024

[View](/lv/documents/product-information/fareston-epar-product-information_lv.pdf)

lietuvių kalba (LT) (175.09 KB - PDF)

**First published:**

30/07/2024

[View](/lt/documents/product-information/fareston-epar-product-information_lt.pdf)

magyar (HU) (177.55 KB - PDF)

**First published:**

30/07/2024

[View](/hu/documents/product-information/fareston-epar-product-information_hu.pdf)

Malti (MT) (203.5 KB - PDF)

**First published:**

30/07/2024

[View](/mt/documents/product-information/fareston-epar-product-information_mt.pdf)

Nederlands (NL) (172.9 KB - PDF)

**First published:**

30/07/2024

[View](/nl/documents/product-information/fareston-epar-product-information_nl.pdf)

norsk (NO) (170.52 KB - PDF)

**First published:**

30/07/2024

[View](/no/documents/product-information/fareston-epar-product-information_no.pdf)

polski (PL) (175.79 KB - PDF)

**First published:**

30/07/2024

[View](/pl/documents/product-information/fareston-epar-product-information_pl.pdf)

português (PT) (172.72 KB - PDF)

**First published:**

30/07/2024

[View](/pt/documents/product-information/fareston-epar-product-information_pt.pdf)

română (RO) (176.25 KB - PDF)

**First published:**

30/07/2024

[View](/ro/documents/product-information/fareston-epar-product-information_ro.pdf)

slovenčina (SK) (167.94 KB - PDF)

**First published:**

30/07/2024

[View](/sk/documents/product-information/fareston-epar-product-information_sk.pdf)

slovenščina (SL) (170.47 KB - PDF)

**First published:**

30/07/2024

[View](/sl/documents/product-information/fareston-epar-product-information_sl.pdf)

Suomi (FI) (165.6 KB - PDF)

**First published:**

30/07/2024

[View](/fi/documents/product-information/fareston-epar-product-information_fi.pdf)

svenska (SV) (166.12 KB - PDF)

**First published:**

30/07/2024

[View](/sv/documents/product-information/fareston-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00002999/202309 26/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fareston : EPAR - All authorised presentations

English (EN) (57 KB - PDF)

**First published:** 17/07/2023

[View](/en/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_en.pdf-0)

[Other languages (24)](#file-language-dropdown-962)

български (BG) (66.82 KB - PDF)

**First published:**

17/07/2023

[View](/bg/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_bg.pdf-0)

español (ES) (57.64 KB - PDF)

**First published:**

17/07/2023

[View](/es/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_es.pdf-0)

čeština (CS) (68.46 KB - PDF)

**First published:**

17/07/2023

[View](/cs/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_cs.pdf-0)

dansk (DA) (58.65 KB - PDF)

**First published:**

17/07/2023

[View](/da/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_da.pdf-0)

Deutsch (DE) (59.61 KB - PDF)

**First published:**

17/07/2023

[View](/de/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_de.pdf-0)

eesti keel (ET) (56.18 KB - PDF)

**First published:**

17/07/2023

[View](/et/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_et.pdf-0)

ελληνικά (EL) (76.79 KB - PDF)

**First published:**

17/07/2023

[View](/el/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_el.pdf-0)

français (FR) (58.76 KB - PDF)

**First published:**

17/07/2023

[View](/fr/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_fr.pdf-0)

hrvatski (HR) (123.65 KB - PDF)

**First published:**

17/07/2023

[View](/hr/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (88.93 KB - PDF)

**First published:**

17/07/2023

[View](/is/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.01 KB - PDF)

**First published:**

17/07/2023

[View](/it/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_it.pdf-0)

latviešu valoda (LV) (78.52 KB - PDF)

**First published:**

17/07/2023

[View](/lv/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_lv.pdf-0)

lietuvių kalba (LT) (79.1 KB - PDF)

**First published:**

17/07/2023

[View](/lt/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_lt.pdf-0)

magyar (HU) (70.63 KB - PDF)

**First published:**

17/07/2023

[View](/hu/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_hu.pdf-0)

Malti (MT) (102.88 KB - PDF)

**First published:**

17/07/2023

[View](/mt/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_mt.pdf-0)

Nederlands (NL) (57.85 KB - PDF)

**First published:**

17/07/2023

[View](/nl/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_nl.pdf-0)

norsk (NO) (88.54 KB - PDF)

**First published:**

17/07/2023

[View](/no/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_no.pdf)

polski (PL) (70.12 KB - PDF)

**First published:**

17/07/2023

[View](/pl/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_pl.pdf-0)

português (PT) (56.42 KB - PDF)

**First published:**

17/07/2023

[View](/pt/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_pt.pdf-0)

română (RO) (135.71 KB - PDF)

**First published:**

17/07/2023

[View](/ro/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_ro.pdf-0)

slovenčina (SK) (70.52 KB - PDF)

**First published:**

17/07/2023

[View](/sk/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_sk.pdf-0)

slovenščina (SL) (56.67 KB - PDF)

**First published:**

17/07/2023

[View](/sl/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_sl.pdf-0)

Suomi (FI) (57.29 KB - PDF)

**First published:**

17/07/2023

[View](/fi/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_fi.pdf-0)

svenska (SV) (58.33 KB - PDF)

**First published:**

17/07/2023

[View](/sv/documents/all-authorised-presentations/fareston-epar-all-authorised-presentations_sv.pdf-0)

## Product details

Name of medicine Fareston Active substance toremifene International non-proprietary name (INN) or common name toremifene Therapeutic area (MeSH) Breast Neoplasms Anatomical therapeutic chemical (ATC) code L02BA02

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.

## Authorisation details

EMA product number EMEA/H/C/000091 Marketing authorisation holder

Orion Corporation

Orionintie 1

Opinion adopted 17/10/1995 Marketing authorisation issued 14/02/1996 Revision 26

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fareston : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (201.49 KB - PDF)

**First published:** 03/04/2009

**Last updated:** 30/07/2024

[View](/en/documents/procedural-steps-after/fareston-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Fareston-H-C-PSUSA-00002999-202309 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/354722/2024

English (EN) (159.43 KB - PDF)

**First published:** 30/07/2024

[View](/en/documents/scientific-conclusion/fareston-h-c-psusa-00002999-202309-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Fareston-H-C-PSUSA-00002999-201709: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/483894/2018

English (EN) (106.7 KB - PDF)

**First published:** 21/08/2018

**Last updated:** 21/08/2018

[View](/en/documents/scientific-conclusion/fareston-h-c-psusa-00002999-201709-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Fareston-H-C-PSUSA-00002999-201409: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/656294/2015

English (EN) (64.73 KB - PDF)

**First published:** 05/10/2015

**Last updated:** 05/10/2015

[View](/en/documents/scientific-conclusion/fareston-h-c-psusa-00002999-201409-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Fareston-H-C-91-2999 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/612251/2014

English (EN) (61.31 KB - PDF)

**First published:** 06/10/2014

**Last updated:** 06/10/2014

[View](/en/documents/scientific-conclusion/fareston-h-c-91-2999-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Fareston : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (90.25 KB - PDF)

**First published:** 29/11/2005

**Last updated:** 29/11/2005

[View](/en/documents/steps-after-cutoff/fareston-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Fareston : EPAR - Scientific discussion

English (EN) (123.43 KB - PDF)

**First published:** 29/11/2005

**Last updated:** 29/11/2005

[View](/en/documents/scientific-discussion/fareston-epar-scientific-discussion_en.pdf)

Fareston : EPAR - Procedural steps taken before authorisation

English (EN) (84.47 KB - PDF)

**First published:** 29/11/2005

**Last updated:** 29/11/2005

[View](/en/documents/procedural-steps/fareston-epar-procedural-steps-taken-authorisation_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 30/07/2024

## Share this page

[Back to top](#main-content)